PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Samsung Biologics publishes prospectus for PolyPeptide public tender offer

  • Direct subsidiary Samsung Peptide AG acting as formal offeror of the public tender offer
  • Publication of offer prospectus follows pre-announcement on July 20, 2026
  • Largest individual shareholder committed to tender all of its PolyPeptide shares into offer
  • Main offer period expected to last from Sept. 15 to Oct. 12, 2026

INCHEON, Korea & ZUG, Switzerland – Aug. 31, 2026 – Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), through its direct Swiss subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the tender offer prospectus (“Offer Prospectus”) for all publicly held registered shares of PolyPeptide Group AG (“PolyPeptide”).

PolyPeptide shareholders will receive CHF 44.31 net in cash for each PolyPeptide share, representing an implied aggregate equity value of approximately CHF 1.46 billion. The offer price represents a 40% premium compared with the unaffected price of PolyPeptide’s shares on the SIX Swiss Exchange (“SIX”) as of April 10, 2026, which was the last trading day prior to the publication of the first media speculation regarding a potential acquisition of PolyPeptide. The offer price represents a premium of 11.6% compared with the volume-weighted average share price over the last 60 trading days prior to the pre-announcement on July 20, 2026.

The Board of Directors of PolyPeptide, acting through its independent and non-conflicted members, unanimously recommends that PolyPeptide’s shareholders accept the offer. The recommendation is further supported by an independent fairness opinion from IFBC AG.

Draupnir Holding B.V., PolyPeptide’s largest individual shareholder, who holds approximately 55.65% of the total PolyPeptide shares outstanding (excluding treasury shares), has undertaken to tender all of its shares into the offer.

The main offer period commences on Sept. 15, 2026 and is expected to end on Oct. 12, 2026 at 4 p.m. Swiss time. The offer is subject to a minimum acceptance threshold of 66⅔% on a fully diluted share count basis (excluding treasury shares), applicable regulatory approvals, and other customary conditions described in the Offer Prospectus. The Offer Prospectus and further offer documentation is available on https://samsungbiologics.com/offer.

Following the settlement of the offer Samsung Peptide intends to pursue a squeeze-out of any remaining minority shareholders and to delist PolyPeptide’s shares from the SIX.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026